Association between elevated prolactin levels and circulating erythroid precursors in dialyzed patients

被引:11
作者
Bellone, G
Rollino, C
Borsa, S
Ferrero, I
Martina, G
Carbone, A
Mareschi, K
Quarello, F
Piccoli, G
Emanuelli, G
Matera, L
机构
[1] Univ Turin, Dept Clin Physiopathol, I-10126 Turin, Italy
[2] Univ Turin, Inst Nephrol, I-10126 Turin, Italy
[3] Univ Turin, Dept Internal Med, I-10126 Turin, Italy
来源
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE | 2000年 / 223卷 / 04期
关键词
D O I
10.1046/j.1525-1373.2000.22352.x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The prolactin (PRL) receptor (R), a member of the cytokine hemopoietin receptor superfamily, has been shown to activate early differentiation steps along the erythroid pathway. In particular PRL, a product of bone marrow stroma, induces functional erythropoietin (EPO)-R on CD34(+) hemopoietic progenitors. In this study, expression of EPO-R mRNA and responsiveness to EPO were assessed on enriched hemopoietic progenitor cells (HPC) from seven hyperprolactinemic and three normoprolactinemic patients and two normal subjects. Expression of EPO-R mRNA by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was found in HPC of four out of seven hyperprolactinemic patients but not in normoprolactinemic patients or normal donors. Development of EPO-dependent Colony Forming Unit-Erythroid (CFU-E) colonies in semi-solid medium was observed only in hyperprolactinemic patients (six out of seven). A much higher number of CFU-E colonies was observed in the four patients with a positive EPO-R message. We conclude from these data that abnormally high levels of PRL may increase the number of EPO-responsive hemopoietic precursors in vivo as they do in vitro. Since hyperprolactinemia associates in these patients with depressed EPO production, it may be regarded as a compensatory mechanism for the reduced availability of the hemopoietic factor.
引用
收藏
页码:367 / 371
页数:5
相关论文
共 27 条
[2]   REGULATORY ACTION OF PROLACTIN ON THE IN-VITRO GROWTH OF CD34+VE HUMAN HEMATOPOIETIC PROGENITOR CELLS [J].
BELLONE, G ;
GEUNA, M ;
CARBONE, A ;
SILVESTRI, S ;
FOA, R ;
EMANUELLI, G ;
MATERA, L .
JOURNAL OF CELLULAR PHYSIOLOGY, 1995, 163 (02) :221-231
[3]  
Bellone G, 1997, BLOOD, V90, P21
[4]  
Bellone G, 1997, J CELL PHYSIOL, V172, P1, DOI 10.1002/(SICI)1097-4652(199707)172:1<1::AID-JCP1>3.0.CO
[5]  
2-S
[6]   REGULATION OF HEMATOPOIESIS INVITRO BY ALLOREACTIVE NATURAL-KILLER-CELL CLONES [J].
BELLONE, G ;
VALIANTE, NM ;
VIALE, O ;
CICCONE, E ;
MORETTA, L ;
TRINCHIERI, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (04) :1117-1125
[7]   SOLUBLE FACTOR(S) RELEASED BY THE PF-382 T-CELL LINE ENHANCES THE STIMULATORY EFFECT OF MONOCYTES ON THE BFU-E GROWTH [J].
BELLONE, G ;
AVANZI, GC ;
LISTA, P ;
HIBBIN, J ;
SAGLIO, G ;
BENETTON, G ;
FOA, R ;
PEGORARO, L .
JOURNAL OF CELLULAR PHYSIOLOGY, 1988, 135 (01) :127-132
[8]  
BOMMER J, 1987, Nephrology Dialysis Transplantation, V2, P238
[9]   ACTIVATED MAST-CELLS PRODUCE INTERLEUKIN-13 [J].
BURD, PR ;
THOMPSON, WC ;
MAX, EE ;
MILLS, FC .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (04) :1373-1380
[10]   PROLACTIN RECEPTOR EXPRESSION IN HUMAN HEMATOPOIETIC TISSUES ANALYZED BY FLOW CYTOFLUOROMETRY [J].
DARDENNE, M ;
DEMORAES, MDL ;
KELLY, PA ;
GAGNERAULT, MC .
ENDOCRINOLOGY, 1994, 134 (05) :2108-2114